Back to Search
Start Over
Randomized trial of granulocyte colony-stimulating factor for spinal cord injury
- Source :
- Brain
- Publication Year :
- 2020
-
Abstract
- Attenuation of the secondary injury of spinal cord injury (SCI) can suppress the spread of spinal cord tissue damage, possibly resulting in spinal cord sparing that can improve functional prognoses. Granulocyte colony-stimulating factor (G-CSF) is a haematological cytokine commonly used to treat neutropenia. Previous reports have shown that G-CSF promotes functional recovery in rodent models of SCI. Based on preclinical results, we conducted early phase clinical trials, showing safety/feasibility and suggestive efficacy. These lines of evidence demonstrate that G-CSF might have therapeutic benefits for acute SCI in humans. To confirm this efficacy and to obtain strong evidence for pharmaceutical approval of G-CSF therapy for SCI, we conducted a phase 3 clinical trial designed as a prospective, randomized, double-blinded and placebo-controlled comparative trial. The current trial included cervical SCI [severity of American Spinal Injury Association (ASIA) Impairment Scale (AIS) B or C] within 48 h after injury. Patients are randomly assigned to G-CSF and placebo groups. The G-CSF group was administered 400 μg/m2/day × 5 days of G-CSF in normal saline via intravenous infusion for five consecutive days. The placebo group was similarly administered a placebo. Allocation was concealed between blinded evaluators of efficacy/safety and those for laboratory data, as G-CSF markedly increases white blood cell counts that can reveal patient treatment. Efficacy and safety were evaluated by blinded observer. Our primary end point was changes in ASIA motor scores from baseline to 3 months after drug administration. Each group includes 44 patients (88 total patients). Our protocol was approved by the Pharmaceuticals and Medical Device Agency in Japan and this trial is funded by the Center for Clinical Trials, Japan Medical Association. There was no significant difference in the primary end point between the G-CSF and the placebo control groups. In contrast, one of the secondary end points showed that the ASIA motor score 6 months (P = 0.062) and 1 year (P = 0.073) after drug administration tend to be higher in the G-CSF group compared with the placebo control group. Moreover, in patients aged over 65 years old, motor recovery 6 months after drug administration showed a strong trend towards a better recovery in the G-CSF treated group (P = 0.056) compared with the control group. The present trial failed to show a significant effect of G-CSF in primary end point although the subanalyses of the present trial suggested potential G-CSF benefits for specific population.<br />Koda et al. present the results of a randomized phase 3 trial comparing granulocyte colony-stimulating factor versus placebo in patients with acute spinal cord injury. While the primary endpoint was not met, a sub-analysis revealed a trend towards superior efficacy of G-CSF versus placebo in an elderly population.
- Subjects :
- 0301 basic medicine
Adult
Male
medicine.medical_specialty
Adolescent
Phases of clinical research
Neutropenia
G-CSF
Placebo
law.invention
03 medical and health sciences
Young Adult
0302 clinical medicine
Randomized controlled trial
Double-Blind Method
law
Internal medicine
Granulocyte Colony-Stimulating Factor
Clinical endpoint
medicine
Humans
Spinal cord injury
Spinal Cord Injuries
Aged
business.industry
AcademicSubjects/SCI01870
clinical trial
Recovery of Function
Middle Aged
medicine.disease
spinal cord injury
Granulocyte colony-stimulating factor
Clinical trial
030104 developmental biology
AcademicSubjects/MED00310
neuroprotection
Female
Neurology (clinical)
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 14602156
- Volume :
- 144
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Brain : a journal of neurology
- Accession number :
- edsair.doi.dedup.....d1fd75cdc1f322e595b414a7d291fffa